HBV antiviral resistance study in Egyptian patients
Part of Digestive system, Infections clinical trials.
This study looks at how common antiviral resistance is in people with chronic hepatitis B who are taking certain medications. It may help doctors better understand which treatments work best for patients in Egypt.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic hepatitis B (positive for HBsAg for more than 6 months).
- You are currently taking one of these medicines: tenofovir (TDF) 300 mg, entecavir (ETV) 0.5 or 1 mg, or lamivudine 100 mg.
- You are 18 years or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks if certain hepatitis B virus mutations can cause resistance to entecavir, a common treatment. It looks at two groups: people who have never been treated and those who have taken lamivudine before.
This study looks at how hepatitis B virus changes in your body, including mutations and drug resistance, using your blood or liver tissue samples. Understanding these changes could help improve treatment for hepatitis B.
This study looks at how common metabolic syndrome and fatty liver disease are in Egyptian patients with chronic hepatitis B (HBV). It aims to understand the link between these conditions and may help guide future care.
This study follows adults with long-term (chronic) hepatitis B to better understand the condition over time. If you have chronic hepatitis B, it may help researchers improve care for people with the infection.
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
This study looks at the genes of people with chronic hepatitis B (HBV) to find why some people's immune cells (B cells and NK cells) stop working properly. The goal is to discover new ways to treat the disease.
Hear when a new Chronic Hepatitis B - Antiviral Drug Resistance - Hepatitis B Virus (HBV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.